ALLO 8-K 2026-11-05

Allogene Therapeutics, Inc. (ALLO) 8-K dated 2026-11-05 — accession 0001628280-26-071040.

Allogene Therapeutics, Inc. (ALLO) is a biotechnology company listed on US.

Allogene Therapeutics, Inc. filed a 8-K on 2026-11-05. Accession 0001628280-26-071040.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ALLO revenue for 2025-12-31 was $0. Net income was -$190.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ALLO currently screens at market cap $258.1M.

Not investment advice. The ALLO SEC hub lists recent forms. The stock page is the research view.